EPS for Exact Sciences (EXAS) Expected At $-0.33; Cominar Real Estate Investment Trust (TSE:CUF.UN) Had 1 Bullish Analysts

June 19, 2018 - By Winifred Garcia

Exact Sciences Corporation (NASDAQ:EXAS) Logo

Analysts expect Exact Sciences Corporation (NASDAQ:EXAS) to report $-0.33 EPS on July, 24.They anticipate $0.06 EPS change or 22.22% from last quarter’s $-0.27 EPS. After having $-0.33 EPS previously, Exact Sciences Corporation’s analysts see 0.00% EPS growth. The stock increased 2.09% or $1.43 during the last trading session, reaching $69.96. About 2.22 million shares traded. Exact Sciences Corporation (NASDAQ:EXAS) has risen 56.13% since June 19, 2017 and is uptrending. It has outperformed by 43.56% the S&P500. Some Historical EXAS News: ; 30/05/2018 – Exact Sciences Applauds American Cancer Society’s Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49; 06/03/2018 – Exact Sciences Names Paul Limburg Co-Chief Medical Officer; 26/04/2018 – EXACT SCIENCES CORP EXAS.O SEES FY 2018 REVENUE $420 MLN TO $430 MLN; 19/03/2018 – Exact Sciences Closes Below 50-Day Moving Average: Technicals; 19/03/2018 – Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Cancer; 06/03/2018 – Detailed Research: Economic Perspectives on Exact Sciences, KapStone Paper and Packaging, Spirit Realty Capital, KLA-Tencor, Ne; 19/03/2018 – Harry Connick, Jr. and Wife and Cancer Survivor Jill Connick Team Up to Urge People 50 and Older to Get Screened for Colon Canc; 17/04/2018 – Exact Sciences Closes Above 200-Day Moving Average: Technicals; 26/04/2018 – EXACT Sciences 1Q Loss $39.4M; 26/04/2018 – EXACT Sciences Sees 2018 Rev $420M-$430M




Among 4 analysts covering Cominar Real Estate Investment Trust (TSE:CUF.UN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Cominar Real Estate Investment Trust had 24 analyst reports since August 7, 2015 according to SRatingsIntel. TD Securities downgraded the stock to “Buy” rating in Friday, August 7 report. The rating was maintained by BMO Capital Markets with “Outperform” on Thursday, August 24. The firm earned “Hold” rating on Friday, March 10 by TD Securities. The rating was maintained by National Bank Canada on Friday, September 23 with “Outperform”. On Friday, March 10 the stock rating was maintained by Scotia Capital with “Sector Perform”. Scotia Capital maintained it with “Sector Perform” rating and $16.50 target in Friday, November 4 report. See Cominar Real Estate Investment Trust (TSE:CUF.UN) latest ratings:

Investors sentiment increased to 1.15 in 2018 Q1. Its up 0.27, from 0.88 in 2017Q4. It improved, as 43 investors sold Exact Sciences Corporation shares while 80 reduced holdings. 54 funds opened positions while 88 raised stakes. 101.92 million shares or 10.20% more from 92.48 million shares in 2017Q4 were reported. Johnson Financial Gp Inc owns 4,572 shares or 0.02% of their US portfolio. Massachusetts Fincl Ser Co Ma has 172,112 shares. Moreover, Gotham Asset Ltd Liability Co has 0.07% invested in Exact Sciences Corporation (NASDAQ:EXAS) for 128,614 shares. Rathbone Brothers Plc reported 0.02% stake. Emerald Mutual Fund Advisers holds 0.51% or 324,204 shares in its portfolio. Parkside Fincl Bank & holds 123 shares. Baystate Wealth Management invested in 0% or 10 shares. Palisade Mgmt Llc Nj has invested 0.02% in Exact Sciences Corporation (NASDAQ:EXAS). Putnam Investments Ltd Llc invested in 0% or 38,121 shares. Moreover, Gofen & Glossberg Ltd Llc Il has 0.01% invested in Exact Sciences Corporation (NASDAQ:EXAS). Hudock Grp Lc reported 50 shares. Prelude Capital Mgmt invested in 1,719 shares or 0.01% of the stock. Schwab Charles Inv Mngmt holds 830,092 shares. Susquehanna Grp Limited Liability Partnership holds 44,195 shares. Fred Alger Mngmt Inc reported 2.84 million shares.

Since January 2, 2018, it had 0 insider buys, and 21 sales for $25.11 million activity. 25,319 shares were sold by Conroy Kevin T, worth $1.07 million. 2,708 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $141,341 were sold by COWARD D SCOTT. 5,512 Exact Sciences Corporation (NASDAQ:EXAS) shares with value of $243,068 were sold by ARORA MANEESH. LIDGARD GRAHAM PETER had sold 27,428 shares worth $1.11M on Friday, February 23. On Friday, February 23 the insider Elliott Jeffrey Thomas sold $126,252. WYZGA MICHAEL S also sold $381,447 worth of Exact Sciences Corporation (NASDAQ:EXAS) shares. Doyle James Edward had sold 3,098 shares worth $126,925.

Among 18 analysts covering EXACT Sciences (NASDAQ:EXAS), 11 have Buy rating, 1 Sell and 6 Hold. Therefore 61% are positive. EXACT Sciences had 78 analyst reports since July 24, 2015 according to SRatingsIntel. Lake Street downgraded Exact Sciences Corporation (NASDAQ:EXAS) on Wednesday, October 7 to “Hold” rating. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by TH Capital on Wednesday, February 22. Jefferies maintained Exact Sciences Corporation (NASDAQ:EXAS) on Tuesday, July 4 with “Buy” rating. Benchmark maintained it with “Hold” rating and $17 target in Wednesday, October 26 report. The stock has “Buy” rating by William Blair on Thursday, March 29. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Bank of America on Tuesday, October 31. The stock of Exact Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Benchmark on Tuesday, October 31. The firm has “Buy” rating by Cowen & Co given on Wednesday, May 31. Robert W. Baird maintained Exact Sciences Corporation (NASDAQ:EXAS) rating on Tuesday, June 5. Robert W. Baird has “Outperform” rating and $66 target. Lake Street upgraded Exact Sciences Corporation (NASDAQ:EXAS) on Friday, July 24 to “Buy” rating.

More important recent Exact Sciences Corporation (NASDAQ:EXAS) news were published by: Seekingalpha.com which released: “Exact Sciences advancing biomarker panel for liver cancer” on June 05, 2018, also Streetinsider.com published article titled: “Exact Sciences (EXAS) PT Raised to ‘Street High’ $85 at Cowen Following Colorguard Survey”, Seekingalpha.com published: “Exact Sciences upsizes and prices of 1.0% convertible senior notes due 2025” on June 08, 2018. More interesting news about Exact Sciences Corporation (NASDAQ:EXAS) was released by: Fool.com and their article: “20 Million More Potential Customers for Cologuard: Time to Buy Exact Sciences Stock?” with publication date: June 04, 2018.

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company has market cap of $8.53 billion. The firm develops the Cologuard, a non-invasive stool DNA screening test for the early detection of colorectal cancer and pre-cancer. It currently has negative earnings. It has a collaboration, license, and purchase agreement with Genzyme Corporation; and license agreement with MAYO Foundation for Medical Education and Research.

Cominar Real Estate Investment Trust engages in the ownership and management of commercial real estate properties in the province of Quebec. The company has market cap of $2.29 billion. As of May 18, 2006, its portfolio comprised 129 properties in the Greater Montreal and Quebec City areas, consisting of 14 office, 28 retail, and 87 industrial and mixed-use buildings representing approximately 9.7 million square feet of leasable area in the Montreal and Quebec City regions. It currently has negative earnings.

Exact Sciences Corporation (NASDAQ:EXAS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.